Gilead Presents New Liver Disease Research at AASLD 2024
核心洞察
Gilead Sciences is presenting over 40 abstracts at The Liver Meeting 2024, showcasing new data across various liver diseases.
Data from the RESPONSE trial will highlight the efficacy and safety of seladelpar (Livdelzi) in patients with PBC (搜索) and compensated cirrhosis.
An interim analysis of the Phase 3 MYR301 study will evaluate the long-term efficacy of bulevirtide monotherapy in chronic HDV (搜索) patients post-treatment.
Gilead Sciences is set to present new research at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 15-19 in San Diego, California. The presentations will include more than 40 abstracts with key data, including 11 abstracts reporting new data on primary biliary cholangitis (搜索) (PBC (搜索)). The research spans viral hepatitis, PBC, and MASH/fibrosis studies, highlighting Gilead's commitment to advancing liver disease (搜索) research.
Seladelpar (Livdelzi) in Primary Biliary Cholangitis (PBC)
Key data from the RESPONSE trial will be presented, demonstrating the efficacy and safety profile of seladelpar (Livdelzi) in individuals with PBC (搜索) and compensated cirrhosis. Additional data will cover the effects of Livdelzi on pruritus (chronic itching), a symptom significantly impacting the quality of life for PBC patients, along with interim long-term efficacy and safety results from the ongoing ASSURE study.
Bulevirtide in Hepatitis Delta Virus (HDV)
Gilead will present an interim analysis of the Phase 3 MYR301 study, which is evaluating individuals living with hepatitis Delta virus (搜索) (HDV (搜索)) who received bulevirtide monotherapy (2 mg for 144 weeks; 10 mg for 144 weeks; or 10 mg for 96 weeks) for chronic HDV and have been off treatment for 48 weeks. The study is evaluating whether or not patients treated with bulevirtide monotherapy for 2-3 years maintained virological and biochemical responses one year after stopping treatment. An additional 144-week analysis of patient-reported outcomes for individuals treated with bulevirtide 2 mg will also be presented, adding to the wealth of long-term data for the treatment for chronic HDV.
Velpatasvir/Sofosbuvir (Epclusa) in Hepatitis C Virus (HCV)
Hepatitis C virus (搜索) (HCV (搜索)) data will include safety and tolerability outcomes for velpatasvir/sofosbuvir (Epclusa) in pregnant individuals with chronic HCV (the STORC study). These results may help clinicians better support pregnant people living with HCV, which in turn may reduce the risk of transmission to infants. Furthermore, real-world findings from the SVR10K study on HCV will be showcased, demonstrating the effects of direct-acting antivirals against all HCV genotypes across diverse regions.
Combination Therapies for Chronic Hepatitis B Virus (HBV)
Late-breaking data from a Phase 2a open-label study assessing the safety and efficacy of novel combination therapies for chronic hepatitis B virus (搜索) (HBV (搜索)) will also be presented by Gilead. The study evaluates therapies containing VIR-2218, selgantolimod, and nivolumab.